Contact UsDiana Bartlett
Assistant Vice President,
Phone: (909) 607-9864
Email: diana_bartlett[at symbol]kgi.edu
TMP Presentations 2007
Project Summaries 2006-07
Team Members: Adam Gross, Tran Pham, Amy Jarvis, Jonathan Chen, Rachel Howden, Kathleen Wang, Nina Bordeaux, Gena Urowksy, Jeffrey Rubinstein, Sunitha Jagannathan, Rajesh Chitta
Team Members: Calvin Chen, Nate Freund, Luke Powers, Luella Sequeira, Chester Wong
Team Members: Asia Chang, Corwin Cole, Jeff Dock, Vincent Eng, Nathan Lee
The goal of the AB TMP is to formulate a new business model by evaluating growth opportunities in genomic education. Market research was conducted to understand the challenges associated with developing such a business model, while a thorough financial analysis assessed the attractiveness of the opportunity. In addition, product concept development has assisted in the evaluation of consumer acceptance. The results of the TMP will allow AB to critically determine the best opportunities in this sector and identify possible pathways for moving forward. The education market can provide AB with a new consumer base with the potential to improve corporate visibility, drive growth both directly and indirectly, and advance general familiarity with genomics.
Team Members: Ivy Chen, Justin Hsiao, Helen Liu, Rachel Melman, Steven Weinstein
The goal of this TMP was to provide analysis of the molecular diagnostics market and to validate requirements of customers for use in routine molecular diagnostic testing. For the analysis of the molecular diagnostics market, the team developed and deployed its own survey among hospital laboratory personnel. This analysis provided quantitative and qualitative descriptions as well as an evaluation of the competitive landscape and market dynamics affecting adoption of new systems. Validation of requirements was conducted via direct contact by interviewing customers in the field. Recommendations were made to assist Beckman Coulter in developing a testing system with respect to identified market drivers and market acceptance.
Team Members: Tim Friedman, Jeff Liepman, Thomas Quirk, Robert Tapella
The team also generated documentation necessary for the transfer of the system to a cGMP manufacturer, and business analyses of the technology and surrounding technologies generated at KGI. The team is delivering a working prototype to BioHelix at the end of the project, which will be used for in-house assay integration. Throughout the development processes, the team worked to overcome both engineering challenges, such as optical system design and thermal control, and business challenges, such as intellectual property, manufacturing compatibility, and commercial considerations.
Team Members: Adam Miller, M. Cavanaugh-Okeefe, Bala Krishna, Josh Oklan, Parvin Rastegar, Victor Chiu
KGI’s team has evaluated improvements to several aspects of the existing DAS assays. At both the DNA extraction and trait detection stages, alternative methods have been tested which improve throughput, reduce operator time, and reduce reagent costs. This assay is automated at DAS and at KGI using Beckman Coulter Biomek liquid handling platforms.
Team Members: Manjiree Karandikar, Sandeep Lad, Prachi Shah, Andrew Hopkins, Sanket Acharya
The team carried out a technical evaluation of the system to assess and optimize performance characteristics, to determine testing and environmental constraints, and analyze generated spectra from given compounds. In addition, the team developed a library of relevant compounds to grade and confirm identity at the point of testing without compromising packaging. Also, the KGI team explored and developed a road-map of the compendial and regulatory requirements for implementation with Gilead commercial products. Possible avenues were discussed with FDA and USP contacts, and referenced with FDA guidance documents. Concurrently, the team developed a scheme to validate the Raman methodology, to enable use with commercial products. The final report creates a pathway for Gilead to use to "Go-live" with this technology for Gilead’s commercial products.
Team Members: Dan Abramzon, Ravi Amin, Li Chen, Jaime Lau, Kerryann Shemeley
The project began with background research to develop a fundamental understanding about oral drug delivery technologies that increase solubility. Secondary industry research was used to generate a list of technologies and vendors that met the scope of the project. Through a process of experimentation, team discussions, and consultations with the team advisor and client, several key parameters were identified as pertinent to evaluating each oral drug delivery company and its technology(s). These parameters included summarizing each technology and all relevant patents and publications, and determining a company’s business development practices with regard to royalty rates and licensing fees. In conjunction with the company evaluations, performance criteria for the searchable database were developed and FileMaker Pro was selected as the database platform. The database was then scripted and developed to meet client specifications including the ability to search by multiple technologies, different physicochemical properties, and specific companies. For the final deliverable, a user-friendly, expandable, multi-search function database containing ~30 drug delivery companies and their respective technology platforms was provided to Gilead Sciences, Foster City.
Team Members: Pradeep Babu, John McNamara, Ryan Peeler, Senthil Purushothaman, Joanna Kang
1. Complete a pilot mapping project
The entrepreneurial nature of the Lnx Research TMP provided significant insight into the workings of a startup company, and the experience will prove valuable in our careers.
Team Members: Jack Austin, Phyllis Chan, Arun Ravi, Peter Vandeventer
Various milestones were set within the scope of the project in order to have defined deliverables. A preliminary analysis of the business side of sample preparation technology was performed. From market analysis and IP investigations, the NG TMP proposed novel designs to Northrop Grumman for review. Finally, the team gathered laboratory data from designs NG selected for further testing and then built and characterized the final design prototype.